Artivion

Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem

On August 6, Artivion Inc. (NYSE:AORT) reported second-quarter 2026 results that read as if two different companies wrote them. Revenue for the quarter ended June 30 climbed 11% on a GAAP basis to $125.8 million, and the company finished assembling what it calls the only complete aortic arch portfolio in its industry. Yet the same […]

Artivion SVP Andrew Green sells $286k in company shares

Artivion Insider Sold Shares Worth $286,656, According to a Recent SEC Filing

Andrew M Green, Senior Vice President, Regulatory and Quality, on September 10, 2026, sold 11,480 sh

Artivion SVP Andrew Green sells $216k in stock

Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales

Artivion stock has delivered a 57.6% gain over the past three years, yet current valuation checks suggest the shares now sit close to their estimated intrinsic value, rather than offering a clear discount. With the Discounted Cash Flow (DCF) estimate and market multiples both pointing to pricing that looks broadly in line with fundamentals, the stock no longer looks obviously cheap or obviously expensive. Artivion is up 57.6% over three years. This means anyone looking at the stock today is...

Artivion (AORT) Bounces As AMDS Launch Narrative Keeps Fair Value In Focus

Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026. Artivion’s recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers. Balance...